| Literature DB >> 20345847 |
Abstract
Inhibitor of κB kinase (IKK) gamma (IKKγ), also known as nuclear factor κB (NF-κB) essential modulator (NEMO), is a component of the IKK complex that is essential for the activation of the NF-κB pathway. The NF-κB pathway plays a major role in the regulation of the expression of genes that are involved in immune response, inflammation, cell adhesion, cell survival and development. As part of the IKK complex, IKKγ plays a regulatory role by linking the complex to upstream signalling molecules. IKKγ contains two coiled-coil regions, a leucine zipper domain and a highly conserved zinc finger domain. Mutations affecting IKKγ have been associated with X-linked hypohidrotic ectodermal dysplasia with immune deficiency (HED-ID), with the majority of these mutations affecting the C-terminal region of the protein where the zinc finger is located. The zinc finger of IKKγ is needed for NF-κB activation in a cell- and stimulus-specific manner. The major mechanism by which the zinc finger plays this role appears to be the recognition of polyubiquitinated upstream signalling intermediates. This assertion reinforces the current notion that ubiquitination plays a major role in mediating protein-protein interactions in the NF-κB signalling pathway. Because the zinc finger domain of IKKγ is very likely involved in mediating interactions with ubiquitinated proteins, investigations that look for upstream activators or inhibitors of the IKK complex that bind to and interact with the zinc finger of IKKγ are required to gain a better insight into the exact roles of this domain and into the pathogenesis of HED-ID.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20345847 PMCID: PMC3823158 DOI: 10.1111/j.1582-4934.2010.01054.x
Source DB: PubMed Journal: J Cell Mol Med ISSN: 1582-1838 Impact factor: 5.310
Fig 1The canonical NF-κB signalling pathway. This is a schematic representation of the signalling pathways that lead to the activation of NF-κB following stimulation by two of the major NF-κB-inducing stimuli, namely the triggering of the TCR and treatment with TNFα. MHC-II, major histocompatibility complex II; Ag, antigen; CD, cluster of differentiation; ZAP-70, zeta-associated protein of 70 kD; PKC, protein kinase C; CARMA1, CARD-MAGUK protein 1; MALT1, mucosa-associated lymphoid tissue lymphoma translocation gene 1; Bcl10, B-cell CLL/lymphoma 10; TNFR1, TNF receptor-1; RIP1, receptor interacting protein 1; TRADD, TNF receptor- associated death domain protein; TRAF2, TNF receptor-associated factor-2; TAK1, TGF-beta activated-kinase 1; MEKK3, MAPK-ERK kinase kinase-3; p-IκBα, phosphorylated IκBα; Ub, ubiquitin chain.
Fig 2The domain structure of IKKγ and its zinc finger. (A) The positions of the two coiled-coil regions, the leucine zipper (LZ) domain and the zinc finger (ZF) domain are depicted. (B) A schematic representation of the zinc finger domain of IKKγ, which extends from amino acid (aa) residues 397 to 419, is shown. Common mutation sites in the region are also indicated with the letter symbol of the amino acid followed by the residue number. The three cysteine residues and the single histidine residue that coordinate a zinc ion are indicated by the lettered circles.
Fig 3A comparative sequence analysis of the C-terminus of IKKγ. Alignment of the amino acid sequence from the C-terminus of the human IKKγ against that from the mouse, rat and bovine IKKγ is presented. The numbers indicate the sequence number of the amino acid residue. An asterisk indicates a position of mismatch.
Mutations in the C-terminus of IKKγ associated with HED-ID
| Change in DNA | Change in protein | Novel amino acid residues | No. of patients | References |
|---|---|---|---|---|
| dupC1161 | P390fsX394 | RGATx | 1 | [ |
| 1167insC | E390fsX394 | RGATx | 6 | [ |
| 1167insC | E390fsX394 | RGATx | 1 | [ |
| 1171G>T | E391X | 3 | [ | |
| 1207C>T | Q403X | 1 | [ | |
| 1217A>T | D406V | 1 | [ | |
| 1218insA | D406fsX419 | EYGHPADTCHGVHx | 1 | [ |
| 1235insC | I412fsX418 | TTCHGVHx | 1 | [ |
| 1249T>C | C417R | 6 | [ | |
| 1250G>A | C417Y | 1 | [ | |
| 1250G>T | C417F | 2 | [ | |
| 1259A>G | 419fsX27 | 27 extra residues | 2 | [ |
Symbols used to designate sequence changes: dup, duplication; ins, insertion; >, substitution; fs, frameshift; X, translation termination site.
These mutations result in the complete loss of the zinc finger domain.
The patient had normal levels of IgM.
These patients had the OL-EDA-ID syndrome.
A summary of the effects of IKKγ zinc finger mutations on NF-κB activity
| C417R | Dendritic cells | Patient | CD154 | Decrease | [ |
| LPS | No effect | ||||
| C417R or D406V | Monocytes | Patient | CD154 | Decrease | [ |
| LPS | No effect | ||||
| TNFα | No effect | ||||
| C417R | B cells | Patient | CD154 | Decrease | [ |
| ZFDa, b | Fibroblasts | Patient | TNFα | Decrease | [ |
| IL-1 | Decrease | ||||
| C389S/C393S | IKKγ-null mouse fibroblasts | Cell line | TNFα | Decrease | [ |
| IL-1 | No effect | ||||
| C417R, D406V or ZFD | IKKγ-null mouse B cells | Cell line | UV | Decrease | [ |
| Etoposide | Decrease | ||||
| LPS | No effect | ||||
| TNFα | No effect | ||||
| C417R | IKKγ-null mouse B cells | Cell line | LPS | Slight decrease | [ |
| IL-1β | Decrease | ||||
| C417R | Human monocytes | Cell line | LPS | Decrease | [ |
| TNFα | Decrease | ||||
| IKKγ-null human T cells | Cell line | TRAF2 | Decrease | ||
| TRAF6 | Decrease | ||||
| C417R or ZFD | IKKγ-null human T cells | Cell line | TNFα | Decrease | [ |
| C417R or D406V | IKKγ-null human T cells | Cell line | TNFα/ | Decrease | [ |
| PMA/ionomycin | Decrease | ||||
| C417R | IKKγ-null human T cells | Cell line | TNFα | Decrease | [ |
ZFD, zinc finger deletion.
Caused by a duplication of nucleotides 1166–1178, which produced a frameshift at P393 residue and then truncated the protein after the addition of four new amino acid residues.
This sequence number refers to the murine IKKγ, whereas all the other sequence numbers in this table refer to the human IKKγ.
TRAF, tumour necrosis factor receptor-associated factor.